hVIVO plc has appointed Angela Hildreth, finance director and chief operating officer of Futura Medical, as chief financial officer and a board director from 18 November 2026. She succeeds interim CFO Richard Cotton, who stepped in when long-serving finance chief Stephen Pinkerton retired at the end of September.
What was announced
In an announcement published on 12 October 2026, hVIVO plc (LSE:HVO) said Angela Hildreth, aged 46, will join as Chief Financial Officer and Board Director with effect from 18 November 2026. She will lead the group's finance function and support a strategy the company describes as focused on disciplined growth and long-term value creation.
She succeeds Richard Cotton, a non-executive director who has been interim CFO since Stephen Pinkerton's retirement. Mr Cotton stays in the interim role until Ms Hildreth starts and, after a handover, will return to his position as a non-executive director.
Chief executive Yamin 'Mo' Khan said: "We are delighted to welcome Angela to hVIVO at an important stage in the Group's development." Ms Hildreth said: "I have been impressed by the strength of the business and look forward to working with Mo, the Board and the wider team."
Who is Angela Hildreth?
Ms Hildreth has been Finance Director and Chief Operating Officer of Futura Medical plc (LSE:FUM) since 2018. She helped guide Futura's transition from research and development to international commercialisation, including European and US regulatory authorisations, commercial partnerships and product launches. She will remain a non-executive director of Futura for a limited period, which is not specified.
Before that she spent seven years at Shield Therapeutics plc, joining in 2011 as Financial Controller and becoming UK Finance Director in 2015; she played a central role in the company's build-out through its 2016 AIM listing. She is also a former independent non-executive director and Audit Committee chair of Aptamer Group plc. The company says she has more than 15 years of financial experience in listed healthcare businesses.
Under the AIM Rules disclosures, her current directorships are Futura Consumer Healthcare Limited, Futura Medical Developments Limited, Futura Medical plc and Quaff Box Limited; her former directorships in the past five years are Aptamer Group plc and Krumpit Limited. She holds no shares or options in hVIVO.
Background to the change
On 15 September 2026 hVIVO announced that Mr Pinkerton would retire after ten years with the company, remaining in post until 30 September. Mr Cotton, previously CFO of listed life-sciences companies including Dechra Pharmaceuticals and Consort Medical, was named interim CFO, and the board said then that it was in the final stages of selecting a permanent successor.
hVIVO describes itself as a full-service clinical development partner and a global leader in human challenge trials, with sites and laboratories in the UK and Germany. Its interim results, also published on 15 September, showed revenue for the six months to 30 June 2026 of £16.3 million, down from £24.2 million, which the company attributed to an expected second-half weighting. It reported an adjusted EBITDA loss of £4.5 million and cash of £13.0 million at 30 June.
The company's own guidance is for 2026 revenue of about £47 million, including about £3 million from CRS Berlin, which it acquired in August 2026, positive adjusted EBITDA in the second half and a low single-digit adjusted EBITDA loss for the full year. It reported a weighted contracted orderbook of £65 million, or £72 million including CRS Berlin.






Please wait processing your request...